TeneoTwo
About TeneoTwo
TeneoTwo is a Healthcare company based in United States, and was acquired by Astrazeneca in July 2022. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Developer of therapeutics for the treatment of cancer. The lead candidate of the company is TNB-486 for B-cell hematologic malignancies, including diffuse large B-cell lymphoma and follicular lymphoma.
- Headquarters United States
- Stage Acquired
- SectorsHealthcare
- Acquired by Astrazeneca (Jul 2022)
- Investors
- Acquired byAstrazeneca
(Jul 2022)
Investors in TeneoTwo
TeneoTwo has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Astrazeneca.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical and biologics products are developed and distributed worldwide. | 1913 | astrazeneca.com | Cambridge, United Kingdom |
Investor details for TeneoTwo
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as TeneoTwo (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about TeneoTwo
TeneoTwo is headquartered in United States.
Developer of therapeutics for the treatment of cancer. The lead candidate of the company is TNB-486 for B-cell hematologic malignancies, including diffuse large B-cell lymphoma and follicular lymphoma.
TeneoTwo has 1 investor. Key investors include Astrazeneca.
Yes. TeneoTwo was acquired by Astrazeneca in July 2022.